Inhibition of Histone Deacetylase-induced Myocardial Repair Is Mediated by c-kit in Infarcted Hearts

Received for publication, May 10, 2012, and in revised form, September 25, 2012. Published, JBC Papers in Press, September 28, 2012, DOI 10.1074/jbc.M112.379115

Ling Zhang‡, Bing Chen‡, Yu Zhao§, Patrycja M. Dubielecka§, Lei Wei‡, Gang J. Qin∥, Y. Eugene Chin‡, Yigang Wang‡∥, and Ting C. Zhao†

From the ‡Department of Surgery, Boston University Medical School, Roger Williams Medical Center, Providence, Rhode Island 02908, the Departments of ‡Medicine and ‡Orthopaedics, Rhode Island Hospital, Brown University Medical School, Providence, Rhode Island 02905, the ‡Cardiovascular Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, and the **Department of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, Cincinnati, Ohio 45267-0529

Background: Histone deacetylases (HDACs) mediate cardiac development and diseases. Results: HDAC inhibition promoted cardiac repairs and neovascularization, which were absent in KitW/KitW-v mice. Preconditioning of c-kit+ cardiac stem cells via HDAC inhibition increased myocardial regeneration.

Conclusion: HDAC inhibition promotes myocardial repair through c-kit signaling.

Significance: This study advances our knowledge of myocardial repair and development of a novel therapeutic strategy for heart diseases.

Histone deacetylases (HDACs) play a critical role in the regulation of gene transcription, cardiac development, and diseases. The aim of this study was to test whether inhibition of HDACs induces myocardial repair and cardiac function restoration through c-kit signaling in mouse myocardial infarction models. Myocardial infarction in wild type KitW/+ and KitW/KitW-v mice was created following thoracotomy by applying permanent ligation to the left anterior descending artery. The HDAC inhibitor, trichostatin A (TSA, 0.1 mg/kg), was intraperitoneally injected daily for a consecutive 8 weeks after myocardial infarction. 5-Bromo-2-deoxyuridine (BrdU, 50 mg/kg) was intraperitoneally delivered every other day to pulse-chase label in vivo endogenous cardiac replication. Eight weeks later, inhibition of HDACs in vivo resulted in an improvement in ventricular functional recovery and the prevention of myocardial remodeling in KitW/+ mice, which was eliminated in KitW/KitW-v mice. HDAC inhibition promoted cardiac repairs and neovascularization in the infarcted myocardium, which were absent in KitW/KitW-v mice. Re-introduction of TSA-treated wild type c-kit+ CSCs into KitW/KitW-v myocardial infarction heart restored myocardial functional improvement and cardiac repair. To further validate that HDAC inhibition stimulates c-kit+ cardiac stem cells (CSCs) to facilitate myocardial repair, GFP+ c-kit+ CSCs were preconditioned with TSA (50 nmol/liter) for 24 h and re-introduced into infarcted hearts for 2 weeks. Preconditioning of c-kit+ CSCs via HDAC inhibition with trichostatin A significantly increased c-kit+ CSC-derived myocytes and microvessels and enhanced functional recovery in myocardial infarction hearts in vivo. Our results provide evidence that HDAC inhibition promotes myocardial repair and prevents cardiac remodeling, which is dependent upon c-kit signaling.

The acetylation and deacetylation of histones play a significant role in the regulation of gene transcription in many cell types (1, 2). Histone acetylation is mediated by histone acetyltransferase. The resulting modification in the structure of chromatin leads to nucleosomal relaxation and altered transcriptional activation. The reverse reaction is mediated by histone deacetylase, which induces deacetylation, chromatin condensation, and transcriptional repression (3–7). Inhibition of HDACs silences fetal gene activation, renders myocytes insensitive to hypertrophic agonists, mitigates cardiac hypertrophy, and prevents cardiac remodeling (8–10). In addition, we and others demonstrated that inhibition of HDACs protects the heart against acute ischemic injury (11–15).

Earlier studies demonstrated that disruption of c-kit impaired myocardial repair in infarcted hearts (16, 17). We have demonstrated that peripheral infusion of c-kit+ stem cells into infarcted hearts increased neovascularization and cardiac functional recovery (13). Pharmacological treatment induced myocardial regeneration via enhanced cardiac c-kit+ cell proliferation and differentiation in the heart (18). Notably, we have recently found that HDAC inhibition preserves cardiac performance and mitigates myocardial remodeling through stimulating cardiac repair, which is related to the increase in c-kit+ cardiac stem cells in post-myocardial infarction (19). It is interesting to investigate whether HDAC inhibition-induced myocardial repair and functional improvements are mediated through the c-kit signaling pathway.

This work was supported, in whole or in part, by National Institutes of Health Grant RO1 HL089405 from NHLBI. This work was also supported by American Heart Association-National Center, Grant 0735458N (to T. C. Z.).

The abbreviations used are: HDAC, histone deacetylase; MI, myocardial infarction; TSA, trichostatin A; CSC, cardiac stem cell; LV, left ventricular; LVDP, left ventricular developed pressure; LV dP/dt max, left ventricular dp/dt max; LV dP/dt min, left ventricular dp/dt min; RPP, rate pressure product; α-SMA, α-smooth muscle actin.

This article contains supplemental Figs. S1–S4.
It has now been recognized that adult hearts harbor distinct populations of cardiac progenitors (20–23), which have the potential to differentiate into cardiomyocytes, endothelia, and vascular smooth muscle cells. Recent studies suggest that stimulation of endogenous cardiac regeneration to achieve de novo cardiac repair is a critical mechanism of cardiac cell therapy (24, 25). It is unknown whether preconditioning of c-kit+ CSCs via HDAC inhibition with TSA could enhance myocardial repair and improve functional recovery when transplanted into MI hearts. In this study, by utilizing c-kit-deficient KitW+/KitW-/- mice, we have demonstrated that HDAC inhibition induces myocardial repair, prevents cardiac remodeling, and improves myocardial functional recovery through c-kit signaling. Furthermore, we have shown that HDAC inhibition preconditions c-kit+ CSCs to facilitate cardiac repair and neovascularization when re-introduced into the infarcted myocardium. The results provide new evidence to develop novel clinical therapeutic approaches for myocardial infarction.

**EXPERIMENTAL PROCEDURES**

Adult 3-month-old male Kit+/+ mice and KitW+/KitW-/- mice were supplied by The Jackson Laboratory (Wilmington, MA). All animal experiments were conducted under a protocol approved by the Institutional Animal Care and Use Committee of the Institute, which conforms to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (Publication No. 85-23, revised 1996).

**In Vivo Myocardial Infarction**—The mouse myocardial infarction model was created following thoracotomy by applying permanent ligation to the left anterior descending artery. Briefly, anesthesia was produced by intraperitoneal injection of sodium pentobarbital at a dose of 50 mg/kg. During the surgical procedure, the adequacy of anesthesia will be monitored with a toe pinch testing to check the animal’s reaction. Mice received a subcutaneous injection of buprenorphine (0.03 mg/kg) 2 h before surgery and also every 12 h post-surgery for 3 days. Mice were placed in a supine position on the operating table. Ventilation was achieved by connecting the endotracheal tube with a rodent ventilator (Harvard, model 683). The chest was then opened with tenotomy scissors. A 7-0 nylon suture was passed with a tapered needle under the left anterior descending coronary artery. Coronary occlusion was induced by ligation with a nylon suture. Upon completion of ligation, the chest was closed by a 5-0 Tricon suture with one layer through the chest wall and muscle and a second layer through the skin and subcutaneous material. We subjected both Kit+/+ mice and the KitW+/KitW-/- mice to myocardial infarction and randomized them into receiving an intraperitoneal injection of vehicle or TSA (0.1 mg/kg intraperitoneal) on a daily basis for 8 weeks. Sham animals underwent placement of the suture without ligation. In addition, additional Kit+/+ and the KitW+/KitW-/- sham mice were exposed to TSA treatments to serve as sham + TSA controls. We extended our experiments to which KitW+/KitW-/- MI hearts were re-introduced 5 × 10⁶ c-kit+ CSCs from Kit+/+ mice, and this allowed us to see whether functional c-kit+ CSCs were essential for myocardial repair and functional restoration. At the end of experiments, animals were euthanized by intraperitoneal injection of pentobarbital (120 mg/kg).

**Measurement of Ventricular Function**—We used Langendorff’s perfused heart preparation, and measurement of left ventricular function was performed. All mice were anesthetized with a lethal intraperitoneal injection of pentobarbital sodium (120 mg/kg). Hearts were rapidly excised and arrested in ice-cold Krebs-Henseleit buffer. They were then cannulated via the ascending aorta for retrograde perfusion by the Langendorff method using Krebs-Henseleit buffer containing (in mM) 110 NaCl, 4.7 KCl, 1.2 MgSO₄, 27.4 H₂O, 25 CaCl₂, 2H₂O, 11 glucose, 1.2 KH₂PO₄, 25 NaHCO₃, and 0.5 EDTA. The buffer, aerated with 95% O₂-5% CO₂ to give a pH of 7.4 at 37 °C, was perfused at a constant pressure of 55 mm Hg. Left ventricular functional analysis was performed using computer software and a computer-based recording system (BIOPAC, Goleta, CA). Measured parameters include left ventricular systolic pressure, heart rate, and left ventricular developed pressure (LVDp), where LVDp is systolic pressure minus left ventricular end-diastolic pressure, and rate pressure product (RPP). RPP will be expressed as the product of LVDp and heart rate. Left ventricular dp/dt max and dp/dt min were obtained. The measurement of left ventricular function is described previously (26).

**Histological Analysis**—Sections (10 μm) were prepared from paraffin-embedded tissues, and sections from apex, mid-left ventricle (LV), and base were stained with Masson’s trichrome according to the manufacturer’s protocol (Sigma). Images of the three sections, from the base to the apex of the left ventricle, were taken using an Olympus BX51 microscope with Spot Advanced software. Infarct scar area and total area of LV were traced manually and measured using Image software (National Institutes of Health). Wall thickness of left ventricle, viable myocardium, and scar size were measured. To quantitate the degree of LV dilation, the LV expansion index was calculated using a modification of the method (27) as follows: expansion index = (LV cavity area/total area) × (noninfarcted region wall thickness/risk region wall thickness).

**Tissue and Cellular Immunocytochemistries**—Cardiac tissues and sections were prepared from the paraffin-embedded hearts as described above. Tissue sections were de-paraffinized for 30 min at 70 °C and subsequently immersed in xylene and ethanol at decreasing concentrations. Slides were then washed in distilled water. Myocytes were identified by α-sarcomeric actinin and smooth muscle cells by anti-α-smooth muscle actin (α-SMA) monoclonal antibody (Sigma). BrdU was used to detect the proliferative cells (Roche Applied Science); Ki67 was used to detect the cycling cells (Novocastra, UK). c-KIT+ cardiac stem cells were labeled with c-kit antibodies (Abcam, UK). GFP-labeled c-kit+ CSC-derived myocytes were detected with polyclonal GFP antibody (Invitrogen). The total number of vessels from each group was calculated and normalized to the tissue area. The stained numbers of each section were counted at ~20 randomized fields of the tissue sections, which were taken in the middle plane of each heart and contained infarct and border regions.

**Isolation and Culture of c-kit+ CSCs**—Adult male ICR mouse cardiac tissues were minced into small pieces and subjected to enzymatic dissociation, and the remaining tissue fragments were cultured as explants in explant medium (Iscove’s modified Dulbecco’s medium with 10% fetal calf serum (FCS), 100
HDAC Inhibition and c-kit Signaling in Myocardial Repair

units/ml penicillin, 100 μg/ml streptomycin, 2 mmol/liter l-glutamine, and 0.1 mmol/liter 2-mercaptoethanol) at 37 °C and 5% CO₂. After 2–3 weeks, small phase-bright cells migrating above the fibroblast layer were formed from adherent explants. To enrich the c-kit⁺ cardiac stem cells, we sorted CD117⁺ cells from collected cells by positive selection with anti-CD117 microbeads (Miltenyi Biotec) using a magnetic cell sorter device from Miltenyi Biotec. Newly isolated c-kit⁺ cardiac cells were seeded at multiwell plates precoated with Matrigel (BD Biosciences) in media designated for cell growth medium (DMEM/F-12, 10% FBS, 200 mmol/liter l-glutamine, 1% nonessential amino acids, 0.1 mmol/liter β-mercaptoethanol, 1000 units/ml leukemia inhibitory factor, 50 units/ml penicillin, and 50 μg/ml streptomycin). Likewise, c-kit⁺ CSCs from KitW⁺/+ mice were also isolated and cultured as described above and utilized to reintroduce into KitW⁻/KitW⁻⁺ MI hearts.

Western Blot Analysis—We prepared samples from c-kit⁺ CSCs and myocardium and performed immunoblotting analysis. Proteins (50 μg/lane) were separated by SDS-PAGE and then transferred onto a nitrocellulose membrane. The membrane was blocked with 5% nonfat dry milk in 1 × Tris-buffered saline containing 0.5% Tween 20 for 1 h. The blots were incubated with their respective polyclonal antibody (1:1000) for 2 h, visualized by incubation with anti-rabbit horseradish peroxidase-conjugated secondary antibody (1:5000) for 1 h, and developed with ECL chemiluminescence detection reagent (Amersham Biosciences).

HDAC Activity Assay in Myocardium—Measurement of HDAC activity in cardiac tissue was conducted using the colorimetric HDAC activity assay kit (BioVision Research, Mountain View, CA).

Establishment of Stable GFP⁺ c-kit⁺ CSCs—To track the fate of transplanted CSCs in the injured hearts, a stable c-kit⁺ CSC cell line expressing GFP was established. Isolated c-kit⁺ cardiac stem cells were transfected with pEGFP using Lipofectamine™ 2000 (Invitrogen) according to the manufacturer’s instructions. The transfected GFP-CSCs were selected with the maintenance of G418 (500 μg/liter) for 2 weeks, and positive colonies were picked up under fluorescent microscopy. Following identification of stably transfected c-kit⁺ CSC cells, c-kit⁺ CSCs were maintained and used for future studies.

In Vivo c-kit⁺ CSC Transplantations in MI Hearts—In another set of experiments, we performed the cell transplantation procedure in MI hearts; 5 × 10⁶ c-kit⁺ CSCs were suspended in 10 μl of PBS and injected into five sites into the border zones of the ischemic LV of ICR mice. The TSA-treated c-kit⁺ CSC group is the same as above except that c-kit⁺ CSCs were stimulated with 50 nmol/liter for 24 h before cell implantation, whereas vehicle (ethanol) was used to treat c-kit⁺ CSCs as control. Sham animals underwent placement of the suture without ligation. Furthermore, additional sham animals receiving c-kit⁺ CSCs treated with or without TSA were also included to exclude the effects of c-kit⁺ CSCs on sham animals. Ventricular function was assessed 2 weeks following MI. The detailed methodology of MI, ventricular functional estimation, and immunochemical staining analysis are described as above. The newly formed myocardium within the heart was identified by the detection of GFP-positive cells in hearts injected with c-kit⁺ CSCs. The detection of GFP signal was used to recognize myocytes with α-sarcomeric actinin and microvessels with α-SMA.

Data Analysis—All data are expressed as means ± S.E. Differences among the groups were analyzed by one-way analysis of variance followed by Bonferroni correction. Student’s unpaired t test was used for two groups. A probability of p < 0.05 was considered to be a significant difference.

RESULTS

HDAC Inhibition Improves the Restoration of Cardiac Function in MI Hearts, Which Diminishes in KitW⁻/KitW⁻⁺ Mice—As shown in Fig. 1A, both baseline ventricular functions are indistinguishable in LV-dP/dtmax, LV-dP/dtmin LV developed pressure, and rate pressure products between KitW⁻/+ mice and KitW⁻/KitW⁻⁺ mice in the presence or absence of HDAC inhibition, suggesting that TSA treatments did not result in significant changes in cardiac functional parameters. In both KitW⁻/+ and KitW⁻/KitW⁻⁺ mice, myocardial infarction led to the depression of ventricular function (p < 0.05 versus sham groups). However, TSA treatment of infarcted KitW⁻/+ mice significantly improved ventricular functional restoration in LV-dP/dtmax (2650 ± 233 mm Hg/s; 1890 ± 86 mm Hg/s, mean ± S.E. p < 0.01), and LV-dP/dtmin (2710 ± 216 mm Hg/s; 1997 ± 120 mm Hg/s, p < 0.05) showed a higher restoration than TSA-treated KitW⁻/KitW⁻⁺ MI animals. In the KitW⁻/+ MI animal, TSA treatment was also associated with an increase in left ventricular developed pressure (106 ± 10 mm Hg; 70 ± 8 mm Hg, p < 0.05) and rate pressure products (37.0 ± 2.0 × 10³ mm Hg/min; 24.0 ± 2.2 × 10³ mm Hg/min) as compared with TSA-treated KitW⁻/KitW⁻⁺ MI mice (Fig. 1A and B). The recovery of LV-dP/dtmax and LV-dP/dtmin in TSA-treated KitW⁻/KitW⁻⁺ MI was not increased from control KitW⁻/+ MI (1887 ± 109 mm Hg/s; 1943 ± 156 mm Hg/s) and control KitW⁻/KitW⁻⁺ MI hearts (1926 ± 156 mm Hg/s; 2006 ± 131 mm Hg/s), respectively. There was not a significant difference in heart rate among groups. Therefore, the favorable effects of HDAC inhibition on myocardial functional restoration completely deteriorated in the KitW⁻/KitW⁻⁺ MI mice. In addition, there was no significant differences in LV developed pressure and rate pressure products between control KitW⁻/+ MI and control KitW⁻/KitW⁻⁺ MI animals in the absence of TSA treatments, which was indistinguishable with TSA-treated KitW⁻/KitW⁻⁺ MI mice. In addition, TSA treatment slightly increased the coronary effluent in KitW⁻/+ MI mice but abrogated the effluent in KitW⁻/KitW⁻⁺ MI mice, although there was no noticeable significant difference. As can be seen in Fig. 1C, the heart/body ratio, an index of hypertrophy, increased after myocardial infarction in both control KitW⁻/+ MI and KitW⁻/KitW⁻⁺ MI mice as compared with sham controls. Hypertrophic response was reduced in the TSA-treated KitW⁻/+ MI hearts (5.9 ± 0.2 mg/g), but the effect of TSA was diminished in KitW⁻/KitW⁻⁺ MI mice (9.4 ± 0.4 mg/g, p < 0.001).

To further confirm the role of TSA-treated c-kit⁺ CSCs on myocardial functional improvement and anti-hypertrophic effects in post-MI heart, we re-introduced TSA-treated c-kit⁺ CSCs into KitW⁻/KitW⁻⁺ MI heart. As shown in supplemental Fig. S1, myocardial functional restoration and heart/body ratio after receiving TSA-treated c-kit⁺ CSCs in KitW⁻/KitW⁻⁺ MI
HDAC Inhibition and c-kit Signaling in Myocardial Repair

HDAC Inhibition Increases Cardiac Proliferation and Endogenous c-kit+ CSCs in MI Hearts In Vivo, Which Is Absent in KitW/W-v Mice—In sham animals, there were rare detectable BrdU-positive myocytes. However, myocardial infarction led to an increase in BrdU-positive stained nuclei and myocytes. As shown in Fig. 3, A, B, and F, and supplemental Fig. S3A, with HDAC inhibition there were significantly more BrdU positive nuclei in infarcted KitW/W-v hearts (127.0 ± 8.4/mm²) as compared with infarcted KitW/W-v hearts (37.4 ± 4.0/mm²; p < 0.001). Additionally, following HDAC inhibition, BrdU-positive myocytes in infarcted KitW/W-v hearts (55.1 ± 2.9/mm²) increased significantly as compared with TSA-treated KitW/W-v hearts (8.6 ± 4.2/mm²; p < 0.001). There were no significant differences in both BrdU-positive nuclei (24.1 ± 1.9/mm²; 30.0 ± 6.0/mm²) and myocytes (2.9 ± 2.0/mm²; 3.4 ± 0.6/mm²) between control KitW/W-v MI and control KitW/W-v MI hearts in the absence of TSA treatments, respectively. Furthermore, HDAC inhibition significantly increased the percentage of nuclei that expressed Ki67 in the infarcted KitW/W-v hearts (114.0 ± 9.3/mm²) as compared with KitW/W-v MI hearts (28.6 ± 2.4/mm²; p < 0.001) (Fig. 3, C, D, and G, and supplemental Fig. S3B). Likewise, Ki67-positive myocytes in KitW/W-v MI hearts increased significantly as compared with KitW/W-v MI hearts (24.0 ± 5.3/mm²; 5.0 ± 0.8/mm²; p < 0.001) following HDAC inhibition. However, without TSA treatment there was no significance difference in Ki67 positively stained nuclei (31.0 ± 7.6/mm²; 25.0 ± 3.6/mm²) and myocytes (5.7 ± 1.3/mm²; 4.0 ± 0.5/mm²) between control KitW/W-v MI and control KitW/W-v MI, respectively. We observed that with HDAC inhibition, cardiac c-kit+ CSCs increased in KitW/W-v MI hearts as compared with KitW/W-v MI cells (0.56 ± 0.04; 1.1 ± 0.1; p < 0.05). However, without TSA treatments, there was no difference in LV expansion between control KitW/W-v MI and control KitW/W-v MI hearts (1.3 ± 0.1; 1.2 ± 0.1). Therefore, the effects of HDAC inhibition on reducing cardiac remodeling were absent in KitW/W-v MI hearts. The parameters aforementioned were indistinguishable between control KitW/W-v MI hearts and control KitW/W-v MI mice without HDAC inhibition. In addition, as shown in supplemental Fig. S2, re-introduction of TSA-treated c-kit+ CSCs into KitW/W-v MI heart reversed myocardial remodeling in control KitW/W-v MI heart. These observations indicate that HDAC inhibition prevents cardiac remodeling, which depends on c-kit.

c-kit Dysfunction Diminishes Anti-cardiac Remodeling Effect of HDAC Inhibition in MI Hearts—Morphometric analysis of infarcted hearts shows severe LV chamber dilatation and infarcted wall thinning (Fig. 2, A–D and E–H). MI hearts that received HDAC inhibition illustrated attenuated LV remodeling, which demonstrated a more viable myocardium (82 ± 1%) and thicker infarcted ventricular wall in MI Kit+/+ mice (0.78 ± 0.07 mm) than those of KitW/W-v MI mice (65 ± 6%; 0.45 ± 0.05 mm, p < 0.05), respectively. There was no difference between control Kit+/+ MI (0.43 ± 0.05 mm) and control KitW/KitW-v MI (0.38 ± 0.59 mm) mice in the absence of TSA treatments. HDAC inhibition reduced scar size in Kit+/+ MI mice (11.0 ± 1.0%), in contrast to the results seen in KitW/KitW-v MI mice (33.7 ± 4.0%, p < 0.01). Scar size was comparable between control infarcted Kit+/+ and control KitW/KitW-v mice in the absence of TSA treatments (26.4 ± 3.5% and 29.3 ± 3.8%). HDAC inhibition resulted in less LV expansion in Kit+/+ mice as compared with KitW/KitW-v mice (0.56 ± 0.04; 1.1 ± 0.1; p < 0.05). However, without TSA treatments, there was no difference in LV expansion between control Kit+/+ MI and control KitW/KitW-v MI mice (1.3 ± 0.1; 1.2 ± 0.1). Therefore, the effects of HDAC inhibition on reducing cardiac remodeling were absent in KitW/KitW-v MI hearts.

Morphometric analysis of infarcted hearts shows severe LV chamber dilatation and infarcted wall thinning (Fig. 2, A–D and E–H). MI hearts that received HDAC inhibition illustrated attenuated LV remodeling, which demonstrated a more viable myocardium (82 ± 1%) and thicker infarcted ventricular wall in MI Kit+/+ mice (0.78 ± 0.07 mm) than those of KitW/W-v MI mice (65 ± 6%; 0.45 ± 0.05 mm, p < 0.05), respectively. There was no difference between control Kit+/+ MI (0.43 ± 0.05 mm) and control KitW/KitW-v MI (0.38 ± 0.59 mm) mice in the absence of TSA treatments. HDAC inhibition reduced scar size in Kit+/+ MI mice (11.0 ± 1.0%), in contrast to the results seen in KitW/KitW-v MI mice (33.7 ± 4.0%, p < 0.01). Scar size was comparable between control infarcted Kit+/+ and control KitW/KitW-v mice in the absence of TSA treatments (26.4 ± 3.5% and 29.3 ± 3.8%). HDAC inhibition resulted in less LV expansion in Kit+/+ mice as compared with KitW/KitW-v mice (0.56 ± 0.04; 1.1 ± 0.1; p < 0.05). However, without TSA treatments, there was no difference in LV expansion between control Kit+/+ MI and control KitW/KitW-v MI mice (1.3 ± 0.1; 1.2 ± 0.1). Therefore, the effects of HDAC inhibition on reducing cardiac remodeling were absent in KitW/KitW-v MI hearts.

Morphometric analysis of infarcted hearts shows severe LV chamber dilatation and infarcted wall thinning (Fig. 2, A–D and E–H). MI hearts that received HDAC inhibition illustrated attenuated LV remodeling, which demonstrated a more viable myocardium (82 ± 1%) and thicker infarcted ventricular wall in MI Kit+/+ mice (0.78 ± 0.07 mm) than those of KitW/W-v MI mice (65 ± 6%; 0.45 ± 0.05 mm, p < 0.05), respectively. There was no difference between control Kit+/+ MI (0.43 ± 0.05 mm) and control KitW/KitW-v MI (0.38 ± 0.59 mm) mice in the absence of TSA treatments. HDAC inhibition reduced scar size in Kit+/+ MI mice (11.0 ± 1.0%), in contrast to the results seen in KitW/KitW-v MI mice (33.7 ± 4.0%, p < 0.01). Scar size was comparable between control infarcted Kit+/+ and control KitW/KitW-v mice in the absence of TSA treatments (26.4 ± 3.5% and 29.3 ± 3.8%). HDAC inhibition resulted in less LV expansion in Kit+/+ mice as compared with KitW/KitW-v mice (0.56 ± 0.04; 1.1 ± 0.1; p < 0.05). However, without TSA treatments, there was no difference in LV expansion between control Kit+/+ MI and control KitW/KitW-v MI mice (1.3 ± 0.1; 1.2 ± 0.1). Therefore, the effects of HDAC inhibition on reducing cardiac remodeling were absent in KitW/KitW-v MI hearts.

Morphometric analysis of infarcted hearts shows severe LV chamber dilatation and infarcted wall thinning (Fig. 2, A–D and E–H). MI hearts that received HDAC inhibition illustrated attenuated LV remodeling, which demonstrated a more viable myocardium (82 ± 1%) and thicker infarcted ventricular wall in MI Kit+/+ mice (0.78 ± 0.07 mm) than those of KitW/W-v MI mice (65 ± 6%; 0.45 ± 0.05 mm, p < 0.05), respectively. There was no difference between control Kit+/+ MI (0.43 ± 0.05 mm) and control KitW/KitW-v MI (0.38 ± 0.59 mm) mice in the absence of TSA treatments. HDAC inhibition reduced scar size in Kit+/+ MI mice (11.0 ± 1.0%), in contrast to the results seen in KitW/KitW-v MI mice (33.7 ± 4.0%, p < 0.01). Scar size was comparable between control infarcted Kit+/+ and control KitW/KitW-v mice in the absence of TSA treatments (26.4 ± 3.5% and 29.3 ± 3.8%). HDAC inhibition resulted in less LV expansion in Kit+/+ mice as compared with KitW/KitW-v mice (0.56 ± 0.04; 1.1 ± 0.1; p < 0.05). However, without TSA treatments, there was no difference in LV expansion between control Kit+/+ MI and control KitW/KitW-v MI mice (1.3 ± 0.1; 1.2 ± 0.1). Therefore, the effects of HDAC inhibition on reducing cardiac remodeling were absent in KitW/KitW-v MI hearts.
compared with Kit\textsuperscript{W}/Kit\textsuperscript{W-v} MI hearts (123.0 ± 12.0/mm\textsuperscript{2}; 34.5 ± 4.5/mm\textsuperscript{2}, \(p < 0.05\)). There was no significant difference in cardiac c-kit\textsuperscript{+} CSCs between control infarcted Kit\textsuperscript{+/+} MI and control Kit\textsuperscript{W}/Kit\textsuperscript{W-v} groups without TSA treatments (Fig. 3, E and H, and supplemental Fig. S3C). In consistency with the marked elevation of mitosis following HDAC inhibition observed above, protein expressions of Ki67 increased upon HDAC inhibition (Fig. 4A). HDAC activity was significantly inhibited by TSA treatments in MI hearts (Fig. 4B). Furthermore, as shown in supplemental Fig. S4, when TSA-treated c-kit\textsuperscript{+} CSCs were re-introduced into Kit\textsuperscript{W}/Kit\textsuperscript{W-v} MI hearts, BrdU, Ki67 positive stained nuclei, myocytes, and c-kit\textsuperscript{+} CSCs increased significantly as compared with control Kit\textsuperscript{W}/Kit\textsuperscript{W-v} MI hearts.

**HDAC Inhibition Enhances Neovascularization, Which Is Eliminated in Kit\textsuperscript{W}/Kit\textsuperscript{W-v} Mice**—Angiogenic responses were examined by immunofluorescent staining for \(\alpha\)-SMA-positive vessel structures. In the border and center of the infarct zone,
α-SMA-positive microvessels were observed. There was no significant difference between control Kit<sup>W</sup>/Kit<sup>W−v</sup> MI and control Kit<sup>+/−</sup> MI heart in the absence of TSA treatment (38.9 ± 0.6/mm<sup>2</sup>; 32.0 ± 0.8/mm<sup>2</sup>). TSA treatment substantially increased α-SMA positive microvessel densities in Kit<sup>+/−</sup> MI hearts (103.0 ± 1.2/mm<sup>2</sup>) (Fig. 5, A and B). However, the formation of α-SMA-positive microvessels induced by TSA were remarkably decreased in Kit<sup>W</sup>/Kit<sup>W−v</sup> mice (42.0 ± 4.9/mm<sup>2</sup>, p < 0.001), indicating that disruption of c-kit signaling abrogated angiogenesis induced by HDAC inhibition. Also, when TSA-treated c-kit<sup>+</sup> CSCs were re-introduced into Kit<sup>W</sup>/Kit<sup>W−v</sup> MI hearts, the formation of α-SMA-positive microvessels increased to a degree that occurred in infarcted Kit<sup>W</sup>/Kit<sup>W−v</sup> animals that were treated with TSA and were significantly higher than the control Kit<sup>W</sup>/Kit<sup>W−v</sup> MI group (supplemental Fig. S4).

Preconditioning c-kit<sup>+</sup> CSCs with TSA Augments Myocardial Repair in CSC-engrafted MI Hearts—We next sought to test whether preconditioning of c-kit<sup>+</sup> CSCs via HDAC inhibition would enhance the c-kit<sup>+</sup> CSC-derived regenerating myocardium in the c-kit<sup>+</sup> CSC-engrafted MI heart. To track the fate of transplanted c-kit<sup>+</sup> CSCs, we established the GFP-positive stable c-kit<sup>+</sup> CSCs using the standard G418 selective method. Sham animals receiving c-kit<sup>+</sup> CSCs in the presence/absence of TSA did not show newly formed myocyte structure. Notably, the newly formed myocytes and α-SMA-positive microvessels derived from GFP<sup>+</sup> c-kit<sup>+</sup> CSCs were observed in the cell-engrafted MI heart. The hearts engrafted with TSA-treated c-kit<sup>+</sup> CSCs showed a significant increase in newly regenerated myocytes and microvessels compared with MI heart-engrafted c-kit<sup>−/−</sup> CSCs only (Fig. 6, A–D). In addition, as shown in Fig. 7, MI hearts receiving TSA-treated c-kit<sup>+</sup> CSCs resulted in a

FIGURE 3. HDAC inhibition stimulates endogenous cardiac regeneration after MI. A–E, quantitative analyses of BrdU, Ki67, and c-Kit<sup>+</sup> CS<sup>C</sup> staining in 20 paraffin-embedded sections per heart. Hearts were fixed and sectioned 8 weeks after MI; F–I, representative images from TSA-treated Kit<sup>+/−</sup> mouse MI and sham hearts. Nuclei were stained in blue (DAPI) and cardiomyocytes in green (α-sarcomeric actinin); BrdU, Ki67, and c-kit were stained in red. α-Sarc Act, α-sarcomeric actinin; Scale bars, 50 μm; the values represent mean ± S.E., ***, p < 0.001 (n = 4–7 hearts/group).
HDAC Inhibition and c-kit Signaling in Myocardial Repair

marked increase in BrdU-positive nuclei (342 ± 9/mm²) as compared with MI hearts receiving c-kit⁺ CSCs alone (261 ± 41/mm²; p < 0.05) and BrdU-positive myocytes (146 ± 7/mm²; 91 ± 11/mm²; p < 0.05), respectively. Likewise, there was an increase in Ki67-stained nuclei (235 ± 34/mm²; 145 ± 8/mm²; p < 0.05) and myocytes (141 ± 9/mm²; 87 ± 5/mm²; p < 0.001) in infarcted hearts receiving TSA-treated c-kit⁺ CSCs as compared with the MI heart receiving c-kit⁺ CSCs alone. We also noticed that BrdU- and Ki67-positive nuclei and myocytes in MI + c-kit⁺ CSCs were higher than control infarcted heart without receiving c-kit⁺ CSCs.

Preconditioning c-kit⁺ CSCs with TSA Improves Cardiac Functional Recovery in c-kit⁺ CSC-engrafted MI Hearts—Sham animals receiving c-kit⁺ CSCs in the presence/absence of TSA did not show differences in ventricular function, suggesting that there is no significant effect of CSCs on sham animals. As shown in Fig. 8A, a significant reduction in left ventricular systolic pressure and developed pressure were observed in infarcted hearts as compared with sham control hearts. MI heart receiving c-kit⁺ CSCs showed a significant improvement in ventricular functional recovery as compared with control MI hearts. Notably, the engraftment of TSA-treated c-kit⁺ CSCs into MI hearts improves the LV-dP/dt max (1998 ± 163 mm Hg/s; 1489 ± 45 mm Hg/s, p < 0.05) to a greater extent than the MI heart receiving c-kit⁺ CSCs alone. The recovery of LV-dP/dt min (2024 ± 138 mm Hg/s) in hearts receiving TSA-treated CSCs was also higher than hearts treated with CSCs only (1458 ± 50 mm Hg/s), although it did not reach significant difference. Likewise, the animal receiving TSA-treated CSCs demonstrated the better recovery in left ventricular developed pressure (92 ± 8 mm Hg; 57 ± 2.5 mm Hg, p < 0.05) and rate pressure product (36.2 ± 4.5 × 10⁵ mm Hg/min; 23.9 ± 1.2 × 10⁵ mm Hg/min, p < 0.05). In addition, engraftment of c-kit⁺ CSCs significantly improved myocardial functional recovery as compared with control MI hearts in which ventricular function included LV-dP/dt max, LV-dP/dt min, LV developed pressure, and rate pressure products. MI resulted in the increase in heart/body ratio, which was reduced in c-kit⁺ CSC-engrafted MI hearts. However, hearts receiving TSA-treated c-kit⁺ CSCs had a decreased heart/body ratio, although it did not cause a significant difference (Fig. 8B). The results further indicate that preconditioning of c-kit⁺ CSCs via HDAC inhibition effectively improves myocardial functional recovery in c-kit⁺ CSC-engrafted MI hearts.

DISCUSSION

Salient Findings—In this study, we demonstrated the following. 1) HDAC inhibition-induced myocardial functional improvement and anti-hypertrophic effect were eliminated by genetic mutation of c-kit in Kit⁺/Kit⁺/⁻ mice. 2) Disruption of c-kit abrogated myocardial repair and neovascularization induced by HDAC inhibition and exacerbated myocardial remodeling in MI hearts. 3) Re-introduction of TSA-treated wild type c-kit⁺ CSCs into Kit⁺/Kit⁻/⁻ MI heart restored myocardial functional improvement and cardiac repair. 4) Preconditioning of c-kit⁺ CSCs with TSA increased the formations of new myocytes and microvessels when reintroduced into infarcted hearts. 5) Engraftment of preconditioned c-kit⁺ CSCs

FIGURE 4. Effect of HDAC inhibition augments the protein expression of Ki67 (A); HDAC activities decreased in Kit⁺/⁻ MI hearts that received TSA treatment (B). Values represent mean ± S.E.; *, p < 0.05 (n = 3/per group).

FIGURE 5. HDAC inhibition-induced angiogenesis diminishes in Kit⁺/⁻ MI hearts. A, quantitative analysis of microvessel formation in MI hearts from Kit⁺/⁻ mice and Kit⁺/Kit⁺/⁻ mice. B, representative images of newly formed α-SMA-positive microvessels in Kit⁺/⁻ mice and Kit⁺/Kit⁺/⁻ MI hearts that received TSA treatment. α-SMA-positive microvessels were stained in red and nuclei in blue. Scale bars, 50 μm; the values represent mean ± S.E., ***, p < 0.001 (n = 4–7 hearts/group).
FIGURE 6. HDAC inhibition enhances myocardial regeneration in c-kit<sup>+</sup> CSC engrafted infarcted hearts. The newly formed cardiomyocytes in MI hearts received TSA-treated GFP <sup>+</sup> c-kit<sup>+</sup> CSCs; cardiomyocytes were stained in green (α-sarcomeric actinin (α-Sarc Act)) and GFP in red (other groups were not shown).

FIGURE 7. Quantitative analysis of BrdU and Ki67 in TSA-treated c-kit<sup>+</sup> CSC-grafted MI hearts. Values represent mean ± S.E.* p < 0.05; ** p < 0.01; *** p < 0.001 (n = 4/group).
via HDAC inhibition resulted in a significant improvement in myocardial functional recovery.

Even though transplantation of stem cells has extensively been performed for tissue regeneration, these strategies are susceptible to immunological rejection (28). Generating functional cardiac myocytes and new microvessels from stimulating in situ the intrinsic resident CSCs appears to be an important strategy, which could elicit immediate repair in acute myocardial infarction. Recent observations from our laboratory show that HDAC inhibition increased c-kit CSCs and promoted endogenous angiomyogenesis in MI heart (19). However, the mechanism(s) by which HDAC inhibition induced cardiac repair to preserve myocardial function is not clear. In this study, we provide new evidence to show that disruption of c-kit in KitW/KitW-v mice eliminated cardiac repair via HDAC inhibition, pointing out a cause and effect relationship between HDAC inhibition and c-kit in inducing myocardial repairs.

The c-kit CSCs have been identified to reconstitute well differentiated myocardium in infarcted hearts (20, 29). Inhibition of HDAC promoted a dramatic increase in c-kit CSCs in the Kit+/+ MI mice but a decrease in KitW/KitW-v mice, suggesting that the reduction of c-kit CSCs is directly associated with an impairment of cardiac repair and myocardial function recovery by disruption of c-kit signaling. In addition, HDAC inhibition-induced angiogenic response presented an association with the improvement in coronary effluents in post-MI Kit+/+ animals compared with KitW/KitW-v mice, supporting that angiogenic response is dependent upon c-kit. It is likely that the increase in angiogenic response in TSA-treated infarcted hearts contributes to the improvement in contractile performance in our studies. It was reported that bone marrow-derived stem cells mobilize to the infarcted area after injury (30). Homing of c-kit-positive cells from bone marrow or transplantation of c-kit+ cells into infarcted hearts was also reported to attribute to myocardial protection and an increase in angiogenesis (31–32). Earlier investigations showed that KitW/ KitW-v c-kit mutant mice developed severe myocardial dilation attributable to infarct expansion in a short term of myocardial infarction (16, 17). Transplantation of wild type bone marrow cells into mutant mice rescued the efficient establishment of
vessel-rich repair tissue, addressing that c-kit\(^+\) cells in bone marrow cells contribute to cardiac repair in a short time MI model. However, we employed an 8-week myocardial infarction model in both Kit\(^+/+\) and Kit\(^W/Kit^{W-}\) c-kit mutant mice. There is no significant difference in magnitude in myocardial repair and myocardial functional recovery in the absence of HDAC inhibition. This suggests that c-kit\(^-\) cells in bone marrow may not be a major factor involved in myocardial repair via HDAC inhibition in the long term for myocardial infarction. In addition, we also showed that there was no significant change in peripheral c-kit\(^+\) stem cell population in the blood after HDAC inhibition (data not shown), but there was a dramatic increase in cardiac c-kit\(^-\) CSCs at 8 weeks after MI, indicating that cardiac c-kit\(^+\) CSCs rather than peripheral c-kit\(^+\) cells contribute mostly to the increased amount of c-kit\(^-\) stem cells in the infarcted hearts after HDAC inhibition. It is also very interesting in the future to elucidate whether specific stem cell types differently mediate cardiac repairs and functional recovery at different times after infarction (long term versus short term MI).

Our observations indicate that at the basal condition, sham animals receiving TSA did not exhibit a noticeable change in cardiac function. However, in infarcted hearts, the administration of TSA in Kit\(^W/Kit^{W-}\) mice showed a lack of improvement in cardiac functional recovery, which is associated with reduction of c-kit\(^+\) CSCs, pointing out that HDAC inhibition-induced myocardial repair and functional improvement require c-kit\(^+\) CSCs. Furthermore, the decrease in myocardial proliferation in Kit\(^W/Kit^{W-}\) MI mice after HDAC inhibition further addresses the dependence of HDAC inhibition on c-kit signaling to induce cardiac repair. Interestingly, transplantation of TSA-treated c-kit\(^-\) CSCs into Kit\(^W/Kit^{W-}\) MI mice could restore cardiac functional improvements, reverse remodeling, and enhance cardiac repair, confirming the evident importance of c-kit signaling in this event. In addition, at the basal level, myocardial proliferations were rarely detectable in sham animals in the presence/absence of TSA treatment.

Preconditioning of c-kit\(^+\) CSCs via HDAC inhibition resulted in increases in c-kit\(^+\) CSC-derived myocardial regeneration, angiogenesis, and improvement of cardiac functional recovery in c-kit\(^+\) CSC-engrafted MI hearts, further validating the role of HDAC inhibition in mediating c-kit\(^+\) CSCs to induce cardiac repair. We also noticed that sham animals, when receiving c-kit\(^-\) CSC engraftment in the presence/absence of TSA treatments, did not demonstrate the newly formed myocyte-like structures. This might suggest that cardiac injury was needed to stimulate the tissue repair when cell engraftments were provided. However, a specific signaling pathway for HDAC inhibition to drive myocardial regeneration still needs to be determined. We have recently found that disruption of NF-κB of c-kit\(^+\) CSCs eliminates HDAC inhibition-induced cardiogenesis.\(^3\) It will be interesting in the future to evaluate whether NF-κB is also involved in c-kit\(^+\) CSC-derived myocardial repair by HDAC inhibition in vivo. In addition, it will be interesting to see whether HDAC inhibition also regulates cardiomyocytes and other cardiac stem cells, which contribute to myocardial repair.

**Conclusion**—In this study, our results indicate that genetic disruption of c-kit in Kit\(^W/Kit^{W-}\) mice abolished the effect of HDAC inhibition-induced myocardial repair, subsequently blocked the restoration of ventricular functional improvements, and prevented cardiac remodeling. In addition, HDAC inhibition promoted neovascularization in the infarcted myocardium, which was absent in Kit\(^W/Kit^{W-}\) mice. Preconditioning of c-kit\(^-\) CSCs via HDAC inhibition enhanced c-kit\(^+\) CSC-derived myocardial repair and functional improvements in c-kit\(^-\) CSC-engrafted MI heart. The evidence suggests that HDAC inhibition induces myocardial repair and neovascularization through functional c-kit. Our study not only provides new insight into our understanding of mechanism(s) of myocardial repair but also holds great promise to developing a potential clinical strategy for heart diseases.

**REFERENCES**

1. Verdin, E., Dequiedt, F., and Kasler, H. G. (2003) Class II histone deacetylases. Versatile regulators. *Trends Genet.* 19, 286–293

2. Vigushin, D. M., and Coombes, R. C. (2004) Targeted histone deacetylase inhibition for cancer therapy. *Curr. Cancer Drug Targets* 4, 205–218

3. Cheung, P., Allis, C. D., and Sassone-Corsi, P. (2000) Signaling to chromatin through histone modifications. *Cell* 103, 263–271

4. Håkanson, I., Tse, C., and Wolfle, A. P. (1998) Structure and function of the core histone N termini. More than meets the eye. *Biochemistry* 37, 17637–17641

5. Luger, K., Mäder, A. W., Richardon, R. K., Sargent, D. F., and Richmond, T. J. (1997) Crystal structure of the nucleosome core particle at 2.8 Å resolution. *Nature* 389, 251–260

6. Strahl, B. D., and Allis, C. D. (2000) The language of covalent histone modifications. *Nature* 403, 41–45

7. Turner, B. M. (2000) Histone acetylation and an epigenetic code. *BioEssays* 22, 836–845

8. Antos, C. L., McKinsey, T. A., Dreitz, M., Hollingsworth, L. M., Zhang, C. L., Schreiber, K., Rindt, H., Gorczynski, R. J., and Olson, E. N. (2003) Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. *J. Biol. Chem.* 278, 28930–28937

9. Lee, T. M., Lin, M. S., and Chang, N. C. (2007) Inhibition of histone deacetylase 6 (HDAC6) blocks cardiac hypertrophy. *Am. J. Physiol. Heart. Circ. Physiol.* 293, H1968–H1977

10. Kook, H. (2006) Inhibition of histone deacetylase 2 (HDAC2) reduces myocardial ischemia-reperfusion injury in mice. *FASEB J.* 20, 3549–3560

11. Lee, T. M., Lin, M. S., and Chang, N. C. (2007) Inhibition of histone deacetylase 2 (HDAC2) blocks cardiac hypertrophy. *Am. J. Physiol. Heart. Circ. Physiol.* 293, H1968–H1977

12. Zhao, T. C., Cheng, G., Zhang, L. X., Tseng, Y. T., and Padbury, J. F. (2007) Inhibition of histone deacetylase 2 (HDAC2) reduces myocardial ischemia-reperfusion injury in mice. *FASEB J.* 22, 3549–3560

13. Zhao, T. C., Cheng, G., Zhang, L. X., Tseng, Y. T., and Padbury, J. F. (2007) Inhibition of histone deacetylase 2 (HDAC2) reduces myocardial ischemia-reperfusion injury in mice. *FASEB J.* 22, 3549–3560

14. Zhao, T. C., Zhang, L. X., Cheng, G., and Liu, J. T. (2007) gp-91 mediates histone deacetylase inhibition-induced cardioprotection. *Biochim. Biophys. Acta.* 1803, 872–880

15. Zhang, L. X., Zhao, Y., Cheng, G., Guo, T. L., Chin, Y. E., Liu, P. Y., and Zhao, T. C. (2010) Targeted deletion of NF-κB p50 diminishes the cardioprotection of histone deacetylase silencing. *Am. J. Physiol. Heart. Circ. Physiol.* 298, H2154–H2163

\(^3\) T. C. Zhao, X. Qin, and Y. Zhao, unpublished data.
HDAC Inhibition and c-kit Signaling in Myocardial Repair

16. Cimini, M., Fazel, S., Zhuo, S., Raymand, M., Fujii, H., Weisel, R. D., and Li, R. K. (2007) c-kit dysfunction impairs myocardial healing after infarction. *Circulation* **116**, 87–82

17. Ayach, B. B., Yoshimatsu, M., Dawood, F., Sun, M., Arab, S., Chen, M., Higuchi, K., Siatskas, C., Lee, P., Lim, H., Zhang, J., Cukerman, E., Stanford, W. L., and Medin, J. A. (2006) Stem cell factor receptor induces progenitor and natural killer cell-mediated cardiac survival and repair after myocardial infarction. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 2304–2309

18. Limana, F., Germani, A., Zacheo, A., Kajstura, J., Di Carlo, A., Borsellino, G., Leoni, O., Palumbo, R., Battistini, L., Rastaldo, R., Müller, S., Pompilio, G., Andrus, P., Bianchi, M. E., and Capogrossi, M. C. (2005) Exogenous high mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. *Circ. Res.* **97**, e73–e83

19. Zhang, L., Qin, X., Zhao, Y., Fast, L., Zhuang, S., Liu, P., Cheng, G., and Zhao, T. C. (2012) Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiogenesis. *J. Pharmacol. Exp. Ther.* **341**, 285–293

20. Beltami, A. P., Barlucchi, L., Torella, D., Baker, M., Limana, F., Chimenti, S., Kasahara, H., Rota, M., Musso, E., Urbanek, K., Leri, A., Kajstura, J., Nadal-Ginard, B., and Anversa, P. (2003) Adult cardiac stem cells are multipotent and support myocardial regeneration. *Cell* **114**, 763–776

21. Laugwitz, K. L., Moretti, A., Lam, J., Gruber, P., Chen, Y., Woodward, S., Lin, L. Z., Cai, C. L., Lu, M. M., Reth, M., Platosyn, O., Yuan, J. X., Evans, S., and Chien, K. R. (2005) Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. *Nature* **433**, 647–653

22. Pfister, O., Mouquet, F., Jain, M., Summer, R., Helmes, M., Fine, A., Coluccia, W. S., and Liao, R. (2005) CD31+ but Not CD31− cardiomyocyte side population cells exhibit functional cardiomyogenic differentiation. *Circ. Res.* **97**, 52–61

23. Oh, H., Bradlute, S. B., Gallardo, T. D., Nakamura, T., Gassukin, V., Mishina, Y., Pocius, J., Michael, L. H., Behringer, R. R., Garry, D. J., Entman, M. L., and Schneider, M. D. (2003) Cardiac progenitor cells from adult myocardium. Homing, differentiation, and fusion after infarction. *Proc. Natl. Acad. Sci. U.S.A.* **100**, 12313–12318

24. Smart, N., Bollini, S., Dubé, K. N., Vieira, J. M., Zhou, B., Davidson, S., Yellon, D., Riegler, J., Price, A. N., Lythgoe, M. F., Pu, W. T., and Riley, P. R. (2011) *De novo* cardiomyocytes from within the activated adult heart after injury. *Nature* **474**, 640–644

25. Ellision, G. M., Torella, D., Dellegrrottagliole, S., Perez-Martinez, C., Perez de Prado, A., Vicinanza, C., Purushothaman, S., Galuppo, V., Iaconetti, C., Waring, C. D., Smith, A., Torella, M., Cuestas Ramon, C., Gonzalo-Orden, J. M., Agosti, V., Indolfi, C., Galiañanes, M., Fernández-Vazquez, F., and Nadal-Ginard, B. (2011) Endogenous cardiac stem cell activation by insulin-like growth factor-1/hepatocyte growth factor intracoronary injection fosters survival and regeneration of the infarcted pig heart. *J. Am. Coll. Cardiol.* **58**, 977–986

26. Tseng, A., Stabila, J., McGonnigal, B., Yano, N., Yang, M. J., Tseng, Y. T., Dovol, P. A., Lum, L. G., Padbury, J. F., and Zhao, T. C. (2010) Effect of disruption of Akt-1 of lin(−)−c-kit(+)+ stem cells on myocardial performance in infarcted heart. *Circ. Res.* **87**, 704–712

27. Cheng, K., Li, T. S., Malliaras, K., Davis, D. R., Zhang, Y., and Marbán, E. (2010) Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiospheres-derived cells in myocardial infarction. *Circ. Res.* **106**, 1570–1581

28. Swijnenburg, R. J., Schreper, S., Govaert, J. A., Cao, F., Ransohoff, K., Sheikh, A. Y., Haddad, M., Connolly, A. J., Davis, M. M., Robbins, R. C., and Wu, J. C. (2008) Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 12991–12996

29. Franssila, I., Bailey, B., Gude, N. A., Cottage, T. C., Muraski, J. A., Emmanuelp, G., Wu, W., Alvarez, R., Rubio, M., Oottolenghi, S., Schaefer, E., and Sussman, M. A. (2008) Evolution of the c-kit-positive cell response to pathological challenge in the myocardium. *Stem Cells* **26**, 1315–1324

30. Orlic, D., Kajstura, J., Chimenti, S., Limana, F., Jakoniuk, I., Quaini, F., Nadal-Ginard, B., Bodine, D. M., Leri, A., and Anversa, P. (2005) Mobilized bone marrow cells repair the infarcted heart, improving function and survival. *Proc. Natl. Acad. Sci. U.S.A.* **98**, 10344–10349

31. Fazel, S., Cimini, M., Chen, L., Li, S., Angoulvant, D., Fedak, P., Verma, S., Weisel, R. D., Keating, A., and Li, R. K. (2006) Cardioprotective c-kit(+) cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. *J. Clin. Invest.* **116**, 1865–1877

32. Jackson, K. A., Majka, S. M., Wang, H., Pocius, J., Hartley, C. J., Majesky, M. W., Entman, M. L., Michael, L. H., Hirschi, K. K., and Goodell, M. A. (2001) Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. *J. Clin. Invest.* **107**, 1395–1402